New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Ocugen, Inc. (OCGN) vs Scribe Therapeutics Inc. (SCTX)

Ocugen, Inc. and Scribe Therapeutics Inc. are both Biotechnology companies. Ocugen, Inc. and Scribe Therapeutics Inc. are of similar size ($250.4M and $248.6M). Across the 5 metrics below, Scribe Therapeutics Inc. leads on 3 and Ocugen, Inc. on 2.

Valuation

Metric OCGN SCTX Biotechnology median
P/E n/m n/m 8.49
P/S 54.65 6.75 8.56
P/B n/m 1.40 2.04
Price to free cash flow n/m — 23.84
EV/EBITDA n/m n/m 0.69
EV/Sales 37.40 0.02 8.00
Earnings yield (25.97%) (80.87%) (35.81%)
Free cash flow yield (24.47%) — (25.41%)

Profitability

Metric OCGN SCTX Biotechnology median
Gross margin 100.00% — 70.18%
Operating margin (1,444.47%) — 0.00%
Net margin (1,367.61%) — 0.00%
Free cash flow margin (1,337.16%) — 0.00%
Return on equity 923.92% — (51.58%)
Return on assets (78.91%) — (45.91%)
Return on invested capital 0.00% — 0.00%

Growth

Metric OCGN SCTX Biotechnology median
Revenue growth (TTM) (11.01%) — 7.20%
EPS growth (last fiscal year) (15.00%) — 29.04%
Revenue growth, 5-year CAGR — — 9.54%
Net income growth, 5-year CAGR — — 0.00%

Health

Metric OCGN SCTX Biotechnology median
Debt to equity (0.10) 0.00 0.00
Current ratio 0.77 4.72 4.79
Net debt to EBITDA (0.17) — 1.01

Dividend

Metric OCGN SCTX Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric OCGN SCTX Biotechnology median
Market cap 248.64m 250.35m 150.57m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack